Aunque estos medicamentos han sido utilizados para tratar la diabetes tipo 2 durante casi dos dcadas, no fue hasta 2021 que la FDA de EE
Key considerations for protein targets: Use ideal body weight (IBW) or adjusted body weight for calculations, not current weight in patients with obesity Distribute protein across meals rather than concentrating in one sitting Monitor for signs of inadequate intake: fatigue, weakness, hair loss, or poor wound healing Reassess needs every 36 months as weight changes Consult with a registered dietitian for personalized recommendations GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists exert their appetite-suppressing effects through multiple mechanisms
The Fertility Question: Weight loss achieved through Wegovy or Zepbound can sometimes restore ovulation, which can be a welcome side effect for women struggling with obesity-related infertility
This extended gastric retention leads to prolonged satiety after meals and a more gradual release of nutrients into the bloodstream, helping reduce sharp post-meal glucose fluctuations
Those using GLP-1 medications solely for weight management (without diabetes) are not at risk for diabetic retinopathy progression, though they should report any visual symptoms promptly given the ongoing investigation of rare non-retinopathy eye events
Recent legislation (H.R.6 of 2019) mandates ePA for Medicare Part D drugs, pushing PBMs to connect to EHRs ( [35] )
.webp)
